

CASE STUDY

Delivering an Entire Phase 4 Trial: Enrolling 1,000 Participants, Including 45% People of Color

The Objective

Velocity was selected to deliver all sites and participants for a Phase 4 vaccine clinical trial. The trial required previously generally healthy adolescents and young adults.

- **Global enrollment goal:** 1,000 participants
- **Velocity enrollment goal:** 1,000 participants across 24 sites (100% of the trial)
- **Target population:** Adolescents and young adults

The Result

Enrollment began in October 2024 and concluded in November 2024. Velocity's 24 sites successfully enrolled all 1,000 participants, including 450 adolescents.

While no formal demographic objectives were set for the trial, Velocity prioritizes enrolling participant populations that mirror U.S. demographics. As a result, >45% of participants identified as people of color — surpassing the U.S. average of 40%.

Velocity delivered 100% of the trial's participants — 1,000 total — >45% of whom identified as people of color.

The Trial

Client: Large pharma Sponsor

Trial: A Phase 4 vaccine trial

Target population: Generally healthy adolescents and young adults with a specific vaccine status

Velocity Sites

United States

- Abilene, TX
- Albuquerque, NM
- Anderson, SC
- Banning, CA (Now San Bernardino)
- Boise, ID
- Cincinnati, OH (BlueAsh)
- Cincinnati, OH (Springdale)
- Cleveland, OH
- Covington, LA
- Durham, NC
- Grand Island, NE
- Gulfport, MS
- Huntington Park, CA
- Lafayette, LA
- Lincoln, NE
- New Orleans, LA
- Omaha, NE
- Phoenix, AZ
- Salt Lake City, UT
- San Diego, CA
- Savannah, GA
- Syracuse, NY
- Valparaiso, IN
- Washington, DC